Transient neonatal myasthenia gravis: estimation of risk and delay is improved

In myasthenia gravis, autoantibodies against the neuromuscular junction cause fluctuating muscle weakness accentuated by exertion. They can cross the placental barrier and lead to transient neonatal myasthenia gravis, with a life-threatening risk of respiratory failure for the baby. This possibility justifies systematic hospital surveillance of newborns born to mothers with myasthenia gravis, for a period that varies according to the teams (at least two days, three days, seven, etc.).

Rather reassuring data

At Ann Arbor University Hospital (US), pediatricians conducted a retrospective study of 147 of these infants, 37 followed by their own team and 110 from case series previously published in the literature. According to their results, published in February 2021:

  • 90% of newborns of mothers with autoimmune myasthenia gravis do not develop transient neonatal myasthenia gravis,
  • for others, symptoms start 1.5 ± 2.6 days after birth and most often include difficulty feeding and hypotonia;
  • a very small proportion of infants (1/147) require intubation for hypoventilation.

The authors suggest that a four-day postnatal observation would be enough, as no child has developed transient neonatal myasthenia gravis after this time. They also reiterate the importance of initiate the discussion with parents during pregnancy.


Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. Kochhar PK, Schumacher RE, Sarkar S. J Perinatol. 2021 Feb 17.